# Bluejay Diagnostics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Bluejay Diagnostics, Inc.).

## Overview

Bluejay Diagnostics, Inc. is a clinical-stage medical diagnostics company developing the Symphony platform, a near-patient testing system that combines an analyzer with single-use protein detection cartridges. The company’s initial focus is an IL-6 test intended to help clinicians assess sepsis risk and patient acuity in critical care settings such as ICUs and emergency rooms. Bluejay does not yet have regulatory clearance for commercialization in the United States, so its business is still in the development and clinical-validation phase. Management’s stated goal is to build a recurring cartridge-based diagnostics business once FDA authorization is obtained, with additional biomarker tests potentially added over time.

## Products & services

• Symphony analyzer platform for near-patient diagnostics
• Single-use protein detection cartridges
• Symphony IL-6 test for sepsis-related risk assessment
• Planned future biomarker tests for other critical care indications
• Research-use-only Symphony devices (under evaluation)

- **Diagnostic analyzer systems** (20%) — The Symphony instrument platform used to run rapid whole-blood tests in critical care settings.
- **Single-use test cartridges** (55%) — Disposable cartridges that perform protein detection and are intended to drive recurring revenue.
- **Sepsis and IL-6 testing** (15%) — The initial clinical application focused on assessing sepsis-related mortality risk and patient acuity.
- **Future biomarker menu expansion** (5%) — Additional tests for cardio-metabolic disease, cancer, and other rapid-testing indications.
- **Research-use-only systems** (5%) — Devices being evaluated for non-clinical research use while regulatory clearance is pending.

- Symphony analyzer platform for near-patient diagnostics
- Single-use protein detection cartridges
- Symphony IL-6 test for sepsis-related risk assessment
- Planned future biomarker tests for other critical care indications
- Research-use-only Symphony devices (under evaluation)

## Customers

Bluejay’s intended customers are hospitals and other critical care facilities that need rapid diagnostic information to guide treatment decisions. The company specifically targets intensive care units, emergency rooms, and long-term acute care facilities in the United States, where turnaround time and patient acuity assessment are especially important. Its planned customer value proposition is to reduce the need for large upfront capital spending by offering financing options for the analyzer while generating recurring cartridge sales. Bluejay also appears to be evaluating research-use-only sales, which would broaden the addressable customer base before full FDA clearance. Because the platform is still pre-commercial, customer demand is currently prospective rather than realized.

- **U.S. hospitals** (primary) — Buy or place Symphony analyzers and cartridges for use in critical care workflows once FDA clearance is obtained.
- **ICUs and emergency departments** (primary) — Use rapid IL-6 testing to support sepsis evaluation and treatment decisions where minutes matter.
- **Long-term acute care facilities** (secondary) — Adopt the platform for ongoing monitoring of high-acuity patients if the test menu and reimbursement case develop.
- **Research-use-only customers** (emerging) — Evaluate Symphony devices for non-diagnostic research applications while commercialization is pending.

- ICUs that need fast IL-6 and sepsis-related decision support
- Emergency rooms that require rapid triage and acuity assessment
- Long-term acute care facilities with high-acuity patient populations
- Hospital systems seeking lower upfront cost through financing options
- Research users evaluating the Symphony device before clinical launch

## Geography

Bluejay is headquartered in Acton, Massachusetts and is organized in the United States, but its commercial footprint is still largely domestic and prospective. Management says it intends to target the largest critical care facilities in the United States first, so near-term business exposure is concentrated in the U.S. healthcare and FDA regulatory environment. The company also has an exclusive global license with Toray outside Japan for key cartridge technology, which creates an international supply and intellectual-property dimension even though end-market sales are expected to be U.S.-focused initially. Cartridge manufacturing has been transferred to a contract manufacturing facility run by Sanyoseiko, adding operational dependence on non-U.S. manufacturing partners. Because the company has no current revenue-generating operations, geography matters mainly through regulatory approval, supply-chain execution, and future market expansion rather than current sales mix.

- Headquartered in Acton, Massachusetts, United States
- Initial commercialization target is the U.S. critical care market
- FDA clearance is required before U.S. sales can begin
- Cartridge manufacturing is being redeveloped with a contract manufacturer
- Toray license is global outside Japan, creating international IP exposure

## Strategy

Bluejay’s strategy is to secure FDA clearance for Symphony and then commercialize a cartridge-driven diagnostics platform in critical care settings. Management is prioritizing clinical validation, including the SYMON-II trial, to support a future 510(k) submission and to demonstrate that the platform can deliver laboratory-quality results in about 20 minutes. A second strategic priority is to stabilize cartridge manufacturing through contract manufacturing partners so the company can meet performance and quality requirements for regulatory filing and eventual scale-up. The company also intends to use financing options for the analyzer and direct and indirect sales channels to reduce adoption friction and accelerate penetration in hospitals. Longer term, Bluejay wants to expand beyond sepsis into additional biomarker indications, which would increase utilization and recurring cartridge revenue per customer.

- **FDA clearance and regulatory submission** (short-term) — Commercialization depends on regulatory authorization, so clinical evidence and 510(k) readiness are the gating items for revenue generation.
- **Manufacturing redevelopment and quality control** (short-term) — The Symphony cartridge supply chain must be reliable and compliant before the product can be submitted and scaled commercially.
- **Commercial model design** (medium-term) — Financing the analyzer and selling consumables is intended to lower adoption barriers and create recurring revenue.
- **Menu expansion beyond sepsis** (long-term) — Additional tests could increase utilization per customer and broaden the addressable market.

- Obtain FDA clearance for Symphony before any U.S. commercialization
- Complete clinical work, including SYMON-II, to support a 510(k) submission
- Redevelop cartridge manufacturing to meet quality and performance requirements
- Use financing options to reduce analyzer upfront cost for hospitals
- Build recurring revenue through single-use cartridge consumption
- Expand the biomarker menu beyond IL-6 and sepsis over time

## Risks

Bluejay faces substantial execution risk because it has no current operating revenue and must still prove that Symphony can achieve regulatory clearance, manufacturing consistency, and clinical utility. The company’s going-concern disclosures show that it will need additional capital to fund operations, clinical trials, and manufacturing redevelopment, and failure to raise funds could force liquidation or abandonment of development work. As a new medical device business, it also faces the usual risks of delayed trials, FDA review uncertainty, reimbursement and adoption hurdles, and competition from established diagnostics companies. Dependence on Toray’s licensed intellectual property and on third-party manufacturing partners adds concentration risk, because any dispute, supply disruption, or technical failure could delay commercialization. Even if cleared, hospital purchasing cycles and the need to prove workflow and clinical value in critical care settings could slow adoption.

- **Imminent capital shortfall and going-concern uncertainty** [critical] — The company has no revenue-generating operations and expects continued negative cash flow, so failure to raise additional capital could force liquidation or cessation of development.
- **Regulatory approval delay or denial** [high] — Symphony cannot be marketed in the U.S. without FDA authorization, and the company’s commercialization timeline depends on successful clinical evidence and submission.
- **Manufacturing process failure or quality issues** [high] — Cartridge redevelopment is still underway, and technical or quality problems could prevent regulatory submission or reliable production.
- **Dependence on licensed intellectual property and third parties** [high] — The Symphony cartridge platform relies on Toray’s licensed IP and external manufacturing partners, creating counterparty and concentration risk.

- Going-concern and financing risk due to lack of operating revenue
- FDA clearance risk for a product that is not yet authorized for sale
- Clinical trial risk if SYMON-II data are insufficient for submission
- Manufacturing and quality risk in cartridge redevelopment and scale-up
- Dependence on Toray IP and third-party contract manufacturers
- Commercial adoption risk in hospital and critical care purchasing cycles

## Accounting

Bluejay’s financial reporting is dominated by development-stage accounting rather than revenue recognition, because the company does not yet generate operating revenue. The most important judgment area is going-concern assessment: management has concluded that substantial doubt exists and that the company will need additional financing, which affects how investors interpret the balance sheet and future viability. Research and development spending, clinical trial costs, and manufacturing redevelopment expenses are likely to drive period-to-period losses and cash burn, making quarterly comparisons volatile and highly dependent on project timing. Equity and warrant financing transactions are also important because the company has funded operations primarily through stock and warrant issuances, which can create dilution and require careful classification and disclosure. As an emerging growth company, Bluejay also uses the extended transition period for new accounting standards, which can affect comparability with larger public peers.

- **Going-concern assessment** — Affects investor assessment of solvency, liquidity, and asset recoverability
- **Development-stage expense recognition** — Creates large operating losses and cash burn with no offsetting sales
- **Equity and warrant financing accounting** — Affects shareholders’ equity, cash balance, and per-share metrics
- **Emerging growth company accounting election** — May affect timing of standard adoption and disclosure comparability

- No operating revenue yet, so results are driven by development expenses and financing activity
- Going-concern disclosure is a key judgment affecting interpretation of the financial statements
- Clinical trial and manufacturing redevelopment costs create volatile quarterly losses
- Equity and warrant financings affect dilution, cash flow, and balance sheet classification
- Emerging growth company status can delay adoption of new accounting standards

---

*Last updated: 2026-08-11T04:46:24.647564+00:00*